Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,300 | 831 | 55.9% |
| Consulting Fee | $9,945 | 6 | 34.1% |
| Travel and Lodging | $2,086 | 9 | 7.1% |
| Education | $822.71 | 24 | 2.8% |
| Gift | $25.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $4,144 | 14 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $3,821 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $3,084 | 76 | $0 (2024) |
| Janssen Biotech, Inc. | $2,643 | 58 | $0 (2023) |
| Amgen Inc. | $2,221 | 35 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,454 | 81 | $0 (2024) |
| Genentech USA, Inc. | $896.77 | 45 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $813.44 | 49 | $0 (2023) |
| GENZYME CORPORATION | $672.08 | 33 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $639.97 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,073 | 13 | E.R. Squibb & Sons, L.L.C. ($353.17) |
| 2023 | $4,211 | 104 | Merck Sharp & Dohme LLC ($2,086) |
| 2022 | $3,555 | 183 | Janssen Biotech, Inc. ($225.72) |
| 2021 | $2,193 | 120 | AstraZeneca Pharmaceuticals LP ($262.11) |
| 2020 | $3,189 | 82 | Amgen Inc. ($1,613) |
| 2019 | $6,231 | 97 | AstraZeneca Pharmaceuticals LP ($2,812) |
| 2018 | $6,320 | 137 | Takeda Pharmaceuticals U.S.A., Inc. ($4,018) |
| 2017 | $2,406 | 135 | Genentech USA, Inc. ($432.56) |
All Payment Transactions
871 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $2.01 | General |
| Category: Oncology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $1.05 | General |
| Category: Oncology | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $126.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $1.91 | General |
| Category: Oncology | ||||||
| 10/17/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $117.27 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $123.84 | General |
| 08/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $119.70 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Lilly USA, LLC | — | Education | In-kind items and services | $74.59 | General |
| 05/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $129.60 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $104.66 | General |
| Category: Oncology | ||||||
| 02/28/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.25 | General |
| 02/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $123.48 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $50.07 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $85.06 | General |
| Category: ONCOLOGY | ||||||
| 08/31/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $138.00 | General |
| Category: Oncology | ||||||
| 08/30/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Oncology | ||||||
| 08/29/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Oncology | ||||||
| 08/28/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $11.17 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 08/23/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.83 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.11 | General |
| Category: Oncology | ||||||
| 08/22/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $0.67 | General |
| Category: Oncology | ||||||
| 08/18/2023 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $11.19 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,448 | 2,963 | $409,093 | $207,436 |
| 2022 | 14 | 1,490 | 2,914 | $390,960 | $191,580 |
| 2021 | 13 | 1,407 | 2,532 | $354,501 | $184,935 |
| 2020 | 12 | 1,339 | 2,560 | $314,133 | $154,601 |
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 296 | 963 | $140,176 | $69,115 | 49.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 244 | 816 | $84,864 | $48,090 | 56.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 229 | 355 | $36,698 | $17,941 | 48.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 123 | 139 | $40,449 | $17,837 | 44.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 99 | 99 | $26,745 | $13,196 | 49.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 113 | 131 | $25,938 | $12,625 | 48.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 81 | 106 | $22,790 | $11,298 | 49.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 90 | 141 | $8,460 | $5,097 | 60.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 50 | $7,450 | $4,486 | 60.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $7,275 | $3,474 | 47.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 44 | 56 | $5,488 | $2,679 | 48.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 15 | 16 | $2,320 | $1,165 | 50.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 48 | 55 | $440.00 | $431.20 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 288 | 1,011 | $148,921 | $71,987 | 48.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 146 | 164 | $47,724 | $23,336 | 48.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 180 | 391 | $40,664 | $20,983 | 51.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 215 | 316 | $32,768 | $15,341 | 46.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 187 | 498 | $29,880 | $14,512 | 48.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 122 | 138 | $27,324 | $13,628 | 49.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 90 | 90 | $24,552 | $12,509 | 50.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 57 | 67 | $14,338 | $7,192 | 50.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $8,512 | $4,020 | 47.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 45 | $6,705 | $3,476 | 51.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 43 | 60 | $5,880 | $2,894 | 49.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 14 | $2,030 | $1,047 | 51.6% |
About Dr. Wederson Claudino, MD
Dr. Wederson Claudino, MD is a Internal Medicine healthcare provider based in Paducah, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2010. The National Provider Identifier (NPI) number assigned to this provider is 1588977391.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wederson Claudino, MD has received a total of $29,178 in payments from pharmaceutical and medical device companies, with $1,073 received in 2024. These payments were reported across 871 transactions from 81 companies. The most common payment nature is "Food and Beverage" ($16,300).
As a Medicare-enrolled provider, Claudino has provided services to 5,684 Medicare beneficiaries, totaling 10,969 services with total Medicare billing of $738,552. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location Paducah, KY
- Active Since 07/21/2010
- Last Updated 10/01/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588977391
Products in Payments
- NINLARO (Drug) $3,982
- LYNPARZA (Drug) $2,949
- IMBRUVICA (Drug) $2,054
- KEYTRUDA (Biological) $1,164
- OPDIVO (Biological) $1,151
- BRUKINSA (Drug) $778.72
- LIBTAYO (Biological) $701.91
- DARZALEX (Biological) $516.29
- KISQALI (Drug) $339.30
- ELITEK (Drug) $297.28
- ZEJULA (Drug) $265.69
- TECENTRIQ (Biological) $263.50
- XTANDI (Drug) $256.40
- Lenvima (Drug) $254.03
- ENHERTU (Biological) $236.64
- TAGRISSO (Drug) $230.73
- Perjeta (Biological) $216.49
- Imbruvica (Drug) $207.11
- ERLEADA (Drug) $194.22
- IMFINZI (Drug) $170.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Paducah
Dr. Martin Rains, M.d, M.D
Internal Medicine — Payments: $48,397
Jacob Elrod, Md, MD
Internal Medicine — Payments: $24,847
Michael Faulkner, M.d, M.D
Internal Medicine — Payments: $16,943
Ryan Frazine, M.d, M.D
Internal Medicine — Payments: $10,062
Dr. Van Meeks, M.d, M.D
Internal Medicine — Payments: $7,786
Mr. Danny Butler, Md, MD
Internal Medicine — Payments: $6,585